Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Article in Spanish | IBECS | ID: ibc-169627

ABSTRACT

El colesterol es un factor de riesgo modificable fundamental en el desarrollo de la enfermedad ateroesclerótica. Numerosos estudios han demostrado que las estatinas son capaces de reducir el colesterol plasmático y disminuir la aparición de complicaciones ateroescleróticas en prevención tanto primaria como secundaria. De hecho, las guías de práctica clínica recomiendan el uso de estatinas como fármacos esenciales en el control de la hipercolesterolemia, y se recomiendan cifras de colesterol unido a lipoproteínas de baja densidad más estrictas para los pacientes con alto riesgo cardiovascular y en prevención secundaria. A pesar de ello, son numerosos los pacientes que no están adecuadamente controlados, lo que se debe a diversos factores dependientes de los fármacos, del médico y de los pacientes. Por ello, existe un importante margen para mejorar el grado de control de los pacientes con hipercolesterolemia (AU)


Cholesterol is a key modifiable risk factor for the development of atherosclerosis. Numerous studies have shown that statins can reduce plasma cholesterol levels and decrease the development of atherosclerotic complications, both in primary and secondary prevention. In fact, clinical practice guidelines recommend the use of statins as essential drugs in the control of hypercholesterolaemia, recommending stricter levels of low-density lipoprotein cholesterol in patients at high cardiovascular risk and in secondary prevention. Despite this, numerous patients are not adequately controlled, which is due to various factors depending on the drugs, the doctor and the patients. Therefore, there is a substantial margin for improvement in the degree of control of patients with hypercholesterolaemia (AU)


Subject(s)
Humans , Cholesterol/therapeutic use , Lipid Metabolism Disorders/diagnosis , Lipid Metabolism Disorders/drug therapy , Risk Factors , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Primary Prevention , Lipid Metabolism , Lipid Metabolism Disorders/complications , Secondary Prevention , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL
...